Telehealth FX

Medications offered

As listed on the provider’s own site. Whether a product is FDA-approved or compounded is the single most important distinction here — we explain why.

• Compounded semaglutide injectionCompounded · not FDA-approved
• Compounded tirzepatide injectionCompounded · not FDA-approved
• Compounded sublingual semaglutide dropsCompounded · not FDA-approved
• Compounded semaglutide tabletsCompounded · not FDA-approved
• Compounded tirzepatide tabletsCompounded · not FDA-approved

What they publish

Telehealth FX publishes 6 of 12 standard terms. Fields marked “not publicly disclosed” were not stated on the pages we captured, and we have not filled those gaps with assumptions. Compare disclosure across providers

Membership / programme fee

None — states no hidden membership fees (as published)

Medication cost

Published from $146/month for compounded semaglutide and from $258/month for compounded tirzepatide; sublingual semaglutide from $199/month; semaglutide tablets from $249/month; tirzepatide tablets from $224.25/month on a ten-month plan or $299/month on a standard four-month subscription. Six-month payment plans and a first-order discount of up to $400 were advertised at capture (as published)

Introductory offer

Advertised savings of up to $400 on a first GLP-1 order at capture.

Insurance

States there are no insurance hurdles; the service is cash-pay.

HSA / FSA

Not publicly disclosed on the pages we captured.

Consultation process

Online intake with a licensed provider review stated within 24 hours, a customised titration schedule, and one-to-one clinician onboarding.

Eligibility

States providers screen for contraindications and monitor progress. Clinical criteria such as a BMI threshold were not published on the pages we captured.

Lab work

Not publicly disclosed on the pages we captured.

Pharmacy fulfilment

States it partners exclusively with verified US-licensed 503A pharmacies, and separately that medications are prepared by state-licensed 503A and 503B compounding pharmacies overseen by licensed pharmacists. States it does not use salt formulations such as semaglutide sodium or unverified research chemicals. The pharmacies are not named.

Shipping

States two-day UPS shipping to your door, and free shipping on the sublingual product.

Support services

Not publicly disclosed on the pages we captured.

Cancellation

Cancellation terms were not published on the pages we captured.

Refunds

Refund terms were not published on the pages we captured.

What stands out

• Publishes a price for every formulation it sells, including the needle-free routes, rather than a single entry figure.
• States explicitly that it does not use semaglutide sodium or other salt formulations, or research chemicals. Salt forms were a specific FDA concern during the compounding boom, so a provider ruling them out in writing is saying something meaningful.
• Offers four needle-free routes — sublingual drops and two tablet formulations — which is a wider oral range than almost anything else in this directory.
• The pharmacy description is not consistent between pages: the about page says it partners exclusively with 503A pharmacies, while a product FAQ refers to both 503A and 503B facilities.
• The tirzepatide tablet page states tirzepatide 'results in the highest average weight loss of any FDA-approved medication class to date' and then offers that class in a compounded daily tablet. The trial evidence behind that claim is for the FDA-approved weekly injection, not for a compounded oral tablet, and the page does not draw that distinction.
• The about page describes its named staff in analytical rather than clinical terms — a 'Lead Bio-Systems Analyst and Clinical Data Director' overseeing educational content — and no prescribing clinician is named.
• No refund or cancellation policy is published.

Questions to ask before you pay

These are things we could not settle from published pages, or that we think are easy to misread. Get answers in writing.

• Oral and sublingual compounded GLP-1s have no published trial evidence for absorption or effect at the doses sold. What evidence supports the tablet you are being offered?
• The site says 503A only in one place and 503A and 503B in another. Which type of facility fills your prescription?
• Who is the prescribing clinician, and what are their credentials? The named staff on the about page are described in data and analysis roles.
• The tirzepatide efficacy figures cited come from trials of the branded weekly injection. Does the same apply to a daily compounded tablet, and on what basis?
• No refund or cancellation terms are published. What happens if you stop on a six-month payment plan?
• Compounded medication is not FDA-approved. Do you understand what that means for oversight and recourse?

Frequently asked